Alyeska Investment Group
HUMA icon

Alyeska Investment Group’s Humacyte HUMA Stock Holding History

Alyeska Investment Group’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.7M Buy
+6,022,925
New +$5.58M 0.01% 508

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Alyeska Investment Group's HUMA Position: Q2 2026 in Review

Alyeska Investment Group opened a new position in Humacyte (HUMA) in Q2 2026: 6,022,925 shares worth $4.7M. The stake represents 0.01% of the portfolio and ranks #508 among its holdings.

158 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Alyeska Investment Group held 6,022,925 shares of Humacyte worth $4.7M as of Q2 2026.
  • Humacyte was a new Alyeska Investment Group position in Q2 2026.
  • Humacyte made up 0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #508 holding.
  • 158 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.